Cancer immune recognition


Our focus

Tumors form highly complex structures comprising many different cell types like cancer and immune cells. In our research, we develop novel computational biology and immuno-informatics tools to better understand the interactions between immune and cancer cells. 


Our projects

Analysis and predictions of antigen presentation and TCR recognition

The diversity of T-cell epitopes in cancer is overwhelming due the heterogeneity of genetic alterations and the polymorphism of HLA genes. To narrow down the most promising candidates, our lab has developed state-of-the-art predictors of HLA-I [Gfeller et al. J Immunol 2018,Gfeller et al. Cell Systems 2023] and HLA-II ligands [Racle et al. Nature Biotech 2019, Racle et al. Immunity 2023], as well as predictors of neo-epitope TCR recognition [Schmidt et al. Cell Rep Med 2021]. These predictions are largely based on high-quality HLA peptidomics data and machine learning algorithms for motif deconvolution [Bassani-Sternberg and Gfeller J Immunol 2016, Racle et al. Nature Biotech 2019, Gfeller et al. Cell Systems 2023]. Our findings also revealed alternative binding modes of HLA ligands [Guillaume et al. PNAS 2018, Racle et al. Immmunity 2023] and enabled us to better understand the properties of the antigen presentation pathways.

Modelling TCR repertoire and specificity

T cells have the ability to generate billions of T-Cell Receptors (TCRs) that can recognize various epitopes displayed on HLA molecules. While information about the presence of specific T cells in a tumor can be obtained with TCR-sequencing technologies, a major challenge remains to know which T cells recognize which epitopes. Together with several experimental collaborators, we are developing machine learning algorithms both for understanding and modelling the properties of the TCR repertoire and unraveling the determinants of TCR specificity for their cognate epitopes.

Bulk and single-cell genomics analyses of tumors

Tumors are composed of heterogeneous cell types, comprising both cancer cells and non-maligant cells. The presence and phenotype of these different cell types plays an important role in tumor progression and response to therapy. Our lab has developed computational tools to simultaneously Estimate the Proportion of Immune and Cancer cells (EPIC) from bulk tumor gene expression data that can quantitatively predict the fraction of all major immune cell types, as well as cancer cells [Racle et al. 2017]. In parallel, we are actively working on single-cell RNA-Seq data analysis for cancer and immunology, to explore cell type heterogeneity in a fully unbiased and marker-free approach [Carmona et al. 2020]. Recently, we have developed a powerful approach to facilitate the analysis of large single-cell genomics data based on the concept of ‘metacells’ (read more about this in [Bilous et al. Bioinformatics 2022]).



UNIL web teasers general.png







News @Gfeller Lab

Deciphering T Cell Specificity: AI Insights into Immune Surveillance

Deciphering T Cell Specificity: AI Insights into Immune Surveillance

Seminars in Immunology review by David Gfeller

Seminars in Immunology review by David Gfeller

Follow us:  





David Gfeller
Associate Professor
Ludwig adjunct scientist

Laboratory D. Gfeller

Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Ludwig Lausanne RGB-crop461x374.jpg (Print)

Phone +41 21 545 10 69


Featured Publication -------

WEB page vignette (5).png

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes
Nov-2019 | Julien Racle...David Gfeller


Ch. des Boveresses 155 - CH-1066 Epalinges
Tel. +41 21 692 59 92
Fax +41 21 692 59 95
Ludwig Cancer ResearchUniversité de LausanneCentre Hospitalier Universitaire Vaudois (CHUV)